Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors

Ghadban, Tarik; Perez, Daniel; Vashist, Yogesh K.; Bockhorn, Maximilian; Koenig, Alexandra M.; Gammal, Alexander T. El; Izbicki, Jakob R.; Metzger, U; Hauswirth, Fabian; Frosina, Denise; Jungbluth, Achim A.

doi:10.1016/j.ejso.2014.03.011

Cited by 9 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The survival analysis further demonstrated that MAGEC2 expression is an independent prognostic factor for HCC patients. Collective studies support the notion that elevated MAGEC2 expression can be observed in different cancers19,20 and that MAGEC2 expression is correlated with several important clinicopathological attributes, including tumour size,21 TNM stage,8 and recurrence 22. Moreover, Zhao et al9 and Figueiredo et al8 described the prognostic role of MAGEC2 in breast cancer and larynx cancer, respectively.…”

Section: Discussionmentioning

confidence: 82%

<p>MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition</p>

Yuan

Shi

et al. 2019

OTT

View full text Add to dashboard Cite

PurposeAlthough MAGEC2 was first cloned from a human hepatocellular carcinoma (HCC) cDNA library by serum screening, the detailed attributes of MAGEC2 in HCC have rarely been elucidated.Patients and methodsIn this study, The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases were consulted to analyse the expression of MAGEC2 mRNA in liver cancer. Immunohistochemistry (IHC) analysis was performed to detect MAGEC2 expression in HCC, and the relationship between MAGEC2 expression and the clinicopathological characteristics of HCC patients was evaluated. Then, we employed the short hairpin (sh)RNA-mediated knockdown of MAGEC2 in HCC cell lines to explore the function of MAGEC2 in HCC development. Finally, the expression of epithelial-mesenchymal transition (EMT) markers in HCC xenografts and clinical samples was investigated.ResultsThe results showed a remarkably higher level of MAGEC2 expression in HCC tissues than in noncancerous tissues, and MAGEC2 expression could be used as an independent prognostic factor for overall survival in HCC. Moreover, sh-MAGEC2 inhibited a series of HCC malignant behaviours both in vitro and in vivo. Finally, decreased MAGEC2 expression and low levels of EMT markers were detected in sh-MAGEC2 xenografts, while increased MAGEC2 expression and high levels of EMT markers were observed in invasive and metastatic HCC samples.ConclusionTaken together, our data imply that MAGEC2 is a novel prognostic marker for HCC and that MAGEC2 significantly promotes HCC tumourigenesis by inducing EMT. Targeting MAGEC2 may provide a promising therapeutic strategy for HCC treatment.

show abstract

Section: Discussionmentioning

confidence: 82%

<p>MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition</p>

Yuan

Shi

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…Cancer testis antigens are currently being investigated for cancer immunotherapy. CT10/MAGE-C2 and GAGE should be explored together with other previously described cancer testis antigens as targets for immunotherapy of gastrointestinal stromal tumors in cases [24]. Tumor cells exposed to interferon-gamma (IFN- γ ) were better recognized by the anti-MAGE-C2(42–50) CTL clone.…”

Section: Discussionmentioning

confidence: 99%

Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer

Zhao

Shalieer

2016

Disease Markers

View full text Add to dashboard Cite

Objective. In the current study, we measured the expression status of melanoma antigen gene c2 (MAGE-C2) in triple-negative breast cancer (TNBC) and analyzed its prognostic with the clinical pathological features of patients with TNBC. Methods. The expressions statuses of MAGE-C2 were detected in TNBC tissues and paracarcinoma tissues by immunohistochemistry, reverse transcription-polymerase chain reaction (RT-PCR), and western blotting. Then, we investigated the relationship of MAGE-C2 expression status and clinicopathological parameters of TNBC patients by the chi-squared test. Finally, we discussed the relations of MAGE-C2 expression state and prognosis of patients with TNBC by Kaplan-Meier method and Cox proportional hazards model. Results. High MAGE-C2 expression was found in 38.18% (42/110) of TNBC tissues. In adjacent tissues it was 9.09% (10/110). High MAGE-C2 expression in TNBC patients was closely associated with lymph node status, tumor node metastasis (TNM) stage, and lymphovascular invasion (P < 0.001). TNBC patients with high MAGE-C2 expression had significantly shorter survival time than low expression patients. We also found that age, lymph node status, TNM stage, lymphovascular invasion, and MAGE-C2 expression status were closely associated with overall survival of TNBC patients (P < 0.05). Conclusion. High MAGE-C2 expression may serve as an independent prognostic factor for TNBC patients.

show abstract

“…It has been reported that 26.7%-40% of GIST patients show CTAs expression [ 168 – 170 ]. G antigen (GAGE) [ 171 ], melanoma-associated antigen (MAGE)-A1 [ 168 , 169 ], MAGE-A3 [ 168 , 169 ], MAGE-A4 [ 168 , 169 ], MAGE-C1 [ 168 , 169 ], MAGE-C2 (CT10) [ 171 ] and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) [ 168 , 169 ] are present in 12%, 9%-14.3%, 8%-14.3%, 13%-14.3%, 15%-25.8%, 10% and 12%-20.0% of GIST patients, respectively. Another two studies, however, have demonstrated that NY-ESO-1 was almost not expressed in GIST [ 172 , 173 ].…”

Section: Immune Checkpoint Mhc and Other Immune Related Genesmentioning

confidence: 99%

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Chen

Yang

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curative surgical resections and tyrosine kinase inhibitors (TKIs) are the main managements for localized GISTs and recurrent/metastatic GISTs, respectively. Despite multi-lines of TKIs treatments prolonged the survival time of recurrent/metastatic GISTs by delaying the relapse and metastasis of the tumor, drug resistance developed quickly and inevitably, and became the huge obstacle for stopping disease progression. Immunotherapy, which is typically represented by immune checkpoint inhibitors (ICIs), has achieved great success in several solid tumors by reactivating the host immune system, and been proposed as an alternative choice for GIST treatment. Substantial efforts have been devoted to the research of immunology and immunotherapy for GIST, and great achievements have been made. Generally, the intratumoral immune cell level and the immune-related gene expressions are influenced by metastasis status, anatomical locations, driver gene mutations of the tumor, and modulated by imatinib therapy. Systemic inflammatory biomarkers are regarded as prognostic indicators of GIST and closely associated with its clinicopathological features. The efficacy of immunotherapy strategies for GIST has been widely explored in pre-clinical cell and mouse models and clinical experiments in human, and some patients did benefit from ICIs. This review comprehensively summarizes the up-to-date advancements of immunology, immunotherapy and research models for GIST, and provides new insights and perspectives for future studies.

show abstract

Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors

Cited by 9 publications

References 31 publications

<p>MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition</p>

<p>MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition</p>

Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Contact Info

Product

Resources

About